| Document |
Document Title |
|
WO/2024/097629A1 |
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
|
|
WO/2024/096707A1 |
The present invention relates to: a composition for preventing or treating Moyamoya disease, comprising, as an active ingredient, miRNAs or extracellular vesicles comprising same; and a composition for preventing or treating Moyamoya dis...
|
|
WO/2024/097229A1 |
Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated dermatological diseases or conditions.
|
|
WO/2024/096656A1 |
The present invention relates to a composition including catechin hydrate as an active ingredient for the prevention, alleviation, or treatment of chronic obstructive pulmonary disease. The catechin hydrate of the present invention signi...
|
|
WO/2024/094170A1 |
Disclosed are an inhibitor compound of ubiquitin-specific protease 1 and a use thereof. The inhibitor compound specifically relates to a compound represented by formula (I) or an enantiomer, a diastereomer, a racemate, a tautomer, a ster...
|
|
WO/2024/094150A1 |
Described herein are NOD-like receptor protein 3 (NLRP3) inflammasome inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder ass...
|
|
WO/2024/097206A1 |
The present invention relates to Compound (A), pharmaceutically acceptable salts thereof, methods of making, and use thereof optionally in combination with one or more additional therapeutic agents for the treatment of disease.
|
|
WO/2024/095175A1 |
Anti SLC2A1 antibodies and antigen binding fragments thereof are disclosed. The antibodies and the fragments are suitable for use in inhibiting tumor cell glucose uptake and for reprogramming tumor cell metabolism toward oxidative phosph...
|
|
WO/2024/096708A1 |
The present disclosure relates to solid forms of pyrimidine compounds, pharmaceutical compositions including the same and methods of use thereof. For example, the disclosure relates to crystalline polymorphs of a compound of Formula 1, o...
|
|
WO/2024/031176A9 |
An injectable cannabidiol formulation for non-IV parenteral administration comprising, consisting essentially of, or consisting of: (a) a solvent system consisting of (i) an effective amount of at least one triglyceride oil; and (ii) an ...
|
|
WO/2024/098032A1 |
Compositions and methods for treating ependymoma, including RELA fusion‑positive ependymoma refractory to temozolomide-based regimens. Methods comprise administering a therapeutically effective amount of an alkylating hexitol or deriva...
|
|
WO/2024/097948A1 |
Provided herein are compounds, including compounds of Formula (I) (e.g., compounds of Formula (I-a)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-c...
|
|
WO/2024/096624A1 |
The present application provides salts and crystalline forms, and polymorphic crystalline forms of (R)-N-(2-(4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl)-5-(
(6-(3-(3,5-difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)a
mino)-4-methoxyp...
|
|
WO/2024/097846A1 |
Provided are pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility for oral administration. Also provides are pharmaceutical formulations comprising sele...
|
|
WO/2024/097855A2 |
The present disclosure provides compounds of the formulae herein (e.g., Formulae (I) and (II)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds,...
|
|
WO/2024/073007A3 |
Presented herein are formulations comprising lyophilized crofelemer, methods of treating short bowel syndrome (SBS), diarrhea associated with SBS, congenital diarrhea disorders (CDDs), or diarrhea associated with CDDs, such as Microvillu...
|
|
WO/2024/098001A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as mel...
|
|
WO/2024/094208A1 |
The present invention relates to a series of cyano-substitute-containing heterocyclic derivatives and a preparation method therefor, and specifically relates to a compound represented by formula (IV), a stereoisomer thereof, and a pharma...
|
|
WO/2024/097868A1 |
This disclosure relates to the structure-- activity relationships for 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin), 4-phosphoryloxy-N-methyltryptamine (baeocystin), and 4-phosphoryloxy-N,N,N-trimethyltryptamine (aeruginascin), as ...
|
|
WO/2024/095311A1 |
The present invention relates to a food composition, a cosmetic composition, or a drug composition that contains an ascorbic acid 2-glucoside basic amino acid salt and an ascorbic acid 2-glucoside alkali metal salt. A composition accordi...
|
|
WO/2024/097284A1 |
Provided herein are methods, uses, and compositions for treating atrial fibrillation in a patient, such as a patient exhibiting hypertrophic cardiomyopathy.
|
|
WO/2024/094526A1 |
The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer.
|
|
WO/2024/097296A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/094171A1 |
A substituted aminopyrimidine compound, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, in particular as an EGFR inhibitor and/or degradation agent and the us...
|
|
WO/2024/098009A1 |
Compositions and methods for treating or preventing a condition related to myocardial infarction and infarct expansion, extension, and/or dilation following a cardiovascular disorder incident (e.g., post-myocardial infarction) using an e...
|
|
WO/2024/092335A1 |
The present invention aims to solve the problems of the prior art by means of a new dermatological, pharmaceutical and/or cosmetic composition comprising sulphur derivatives, which is particularly useful for topical application before ra...
|
|
WO/2024/097953A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
|
|
WO/2024/097940A1 |
Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A. Provided herein are also methods of treating and/or managing cancers, which comprise administering to a patient Compou...
|
|
WO/2024/097415A1 |
A tumescent solution including: a vasoconstrictor; a B vitamin and a pharmaceutically acceptable carrier. In some examples, the tumescent solution further includes a drug or therapeutic agent dissolved in the tumescent solution. Some exa...
|
|
WO/2024/072931A3 |
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a the...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/097327A1 |
The present invention features formulations and methods for the treatment of an emotional disorder or sexual dysfunction in a subject by administering to the subject a cannabinoid, such as (-)- trans-Δ8-tetrahydrocannabinol (delta-8-THC...
|
|
WO/2024/097521A2 |
In some aspects, the disclosure relates to compositions and methods for modulating (e.g., increasing and/or decreasing) expression of COL1A1 or COL1A2 in a subject. In some aspects, the disclosure provides isolated nucleic acids, and vec...
|
|
WO/2024/098078A2 |
The present disclosure is directed to the use of a composition comprised of: (1) a first active blend of at least: (a) Jojoba oil/Macadamia seed oil esters; (b) squalene; (c) phytosteryl macadamiate; and (d) phytosterols; (2) a second ac...
|
|
WO/2024/092959A1 |
Provided are use of Coclaurine and a derivative thereof in improving NAMPT activity and a pharmaceutical composition. By screening for drug molecule monomers of natural products with NAMPT activation activity using a biological fluoresce...
|
|
WO/2024/059210A3 |
Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatr...
|
|
WO/2024/073420A3 |
Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripher...
|
|
WO/2024/096445A1 |
The present invention relates to a composition for ameliorating, preventing, or treating stress and depression-related diseases, the composition containing talampanel. The talampanel in the present invention has excellent antidepressant ...
|
|
WO/2024/095964A1 |
The present invention addresses the problem of developing an antibody-drug complex containing a TLR7/8 dual agonist compound or a salt thereof to provide a pharmaceutical composition used for the prevention or treatment of various types ...
|
|
WO/2024/095303A1 |
The purpose of the present invention is to provide a composition that can improve, suppress reduction of, or maintain energy production, that is effective in improving, suppressing reduction of, or maintaining energy production, and that...
|
|
WO/2024/095144A1 |
The present application relates to lipidic nanoparticles that are suitable for the treatment of neurologic or chronic diseases. The lipidic nanoparticles of the present application are of the solid lipid nanoparticles or nanostructured l...
|
|
WO/2024/097848A1 |
The present application provides salts and crystalline forms, and polymorphic crystalline forms of (R)-N-(2-(4-(4-cyclopropylpiperazin-l-yl)piperidin-l-yl)-5-(
(6-(3-(3,5- difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-met
hoxy...
|
|
WO/2024/096214A1 |
A composition containing gomisin G as an active ingredient, according to the present invention, has been confirmed to inhibit protein expression of myostatin, atrogin1, MuRF1 which are involved in muscle degradation, and it has been conf...
|
|
WO/2024/098062A2 |
The present disclosure provides a sprayable composition comprising about 1% w/v to about 20% w/v of oxybutynin, a penetration enhancer, at least 65% w/v of an aliphatic solvent, and a film forming excipient, wherein the film forming exci...
|
|
WO/2024/095992A1 |
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (...
|
|
WO/2024/094163A1 |
Disclosed are a polycyclic ring-fused derivative, a preparation method therefor, and use thereof. In particular, disclosed are a compound represented by general formula (I-2-1), a preparation method therefor, a pharmaceutical composition...
|
|
WO/2024/097960A1 |
The presently-disclosed subject matter provides a compound of Formula (I): or a pharmaceutically acceptable salt of the compound, wherein R1 is C1-4 alkyl, C1-4 alkene,,, or, wherein R3, R4, R5, and R6 are independently hydrogen or halog...
|
|
WO/2024/094605A1 |
A composition contains a combination of at least one fiber and at least one probiotic and is formulated for administration to a subject in a condition of challenged gut microbiome such that the combination of at least one fiber and at le...
|
|
WO/2024/095290A1 |
A microplastic-degradation composition comprising: a first phytoconstituent derived from Curcuma Longa, said first phytoconstituent being bisdemethoxycurcumin (Curcumin III); a second phytoconstituent derived from Piper nigrum, said seco...
|
|
WO/2024/097977A1 |
Methods disclosed herein relate to generating silk nanoparticles with a low polydispersity index (PDI). Methods include adding a silk solution dropwise into a volatile solvent that is miscible with water, thereby forming a precipitate-be...
|
